Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Patient Preference and Adherence
|
November 26, 2009
Compliance with RSV prophylaxis: Global physicians' perspectives
Kari S Anderson, Victoria M Mullally, Linda M Fredrick, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
|
May 1, 2012
Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants
Colleen M Wegzyn, Linda M Fredrick, Roxann O Stubbs, et al.
HIV Clinical Trials
|
June 3, 2009
Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe
Sibtain Rahim, Linda M Fredrick, Barbara A da Silva, et al.
HIV Clinical Trials
|
December 20, 2011
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results
Jacques Reynes, Adebayo Lawal, Federico Pulido, et al.
The Journal of Pediatrics
|
June 26, 2007
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing
Eric A F Simoes, Jessie R Groothuis, Xavier Carbonell-Estrany, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 6, 2010
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks
Roberto Zajdenverg, Thomas J Podsadecki, Sharlaa Badal-Faesen, et al.
Journal of Hepatology
|
November 26, 2025
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C
Josep M Llibre, Christoph Boesecke, Juhi Moon, et al.
The International Journal on Drug Policy
|
February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Jason Grebely, Gregory J Dore, Negar N Alami, et al.
Hepatology (Baltimore, Md.)
|
May 20, 2024
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study
Stanislas Pol, Alexander J Thompson, Michelle Collins, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection
Eli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Patient Preference and Adherence
|
November 26, 2009
Compliance with RSV prophylaxis: Global physicians' perspectives
Kari S Anderson, Victoria M Mullally, Linda M Fredrick, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
|
May 1, 2012
Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants
Colleen M Wegzyn, Linda M Fredrick, Roxann O Stubbs, et al.
HIV Clinical Trials
|
June 3, 2009
Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe
Sibtain Rahim, Linda M Fredrick, Barbara A da Silva, et al.
HIV Clinical Trials
|
December 20, 2011
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results
Jacques Reynes, Adebayo Lawal, Federico Pulido, et al.
The Journal of Pediatrics
|
June 26, 2007
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing
Eric A F Simoes, Jessie R Groothuis, Xavier Carbonell-Estrany, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 6, 2010
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks
Roberto Zajdenverg, Thomas J Podsadecki, Sharlaa Badal-Faesen, et al.
Journal of Hepatology
|
November 26, 2025
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C
Josep M Llibre, Christoph Boesecke, Juhi Moon, et al.
The International Journal on Drug Policy
|
February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Jason Grebely, Gregory J Dore, Negar N Alami, et al.
Hepatology (Baltimore, Md.)
|
May 20, 2024
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study
Stanislas Pol, Alexander J Thompson, Michelle Collins, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection
Eli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Page
of 2